High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry

Clinica Chimica Acta

Volumn 429, Issue , 2014, Pages 51-58

  Patteet, Lisbeth ^a,b   Maudens, Kristof E ^a   Sabbe, Bernard ^c,d   Morrens, Manuel ^b,e   De Doncker, Mireille ^b   Neels, Hugo ^a,b  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Stuivenberg General Hospital   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d Psychiatric Centre Sint Norbertushuis   (Belgium)

^e Psychiatric Hospital Broeders Alexianen   (Belgium)

Author keywords

Antipsychotics; Mass spectrometry; Neuroleptics; Therapeutic drug monitoring; UHPLC MS MS

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; BROMPERIDOL; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; ZUCLOPENTHIXOL;

ACCURACY; ANALYSIS; ARTICLE; CALIBRATION; CONCENTRATION (PARAMETERS); DILUTION; DRUG DETERMINATION; ELUTION; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; LIMIT OF QUANTITATION; LIQUID LIQUID EXTRACTION; MULTIPLE REACTION MONITORING; NORMAL HUMAN; PRIORITY JOURNAL; SEPARATION TECHNIQUE; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

7-HYDROXY-N-DESALKYL-QUETIAPINE; 7-HYDROXY-QUETIAPINE; 7OH-NDA-QUE; 7OH-QUE; AGNP; AMI; AMISULPRIDE; ANTIPSYCHOTICS; AP; ARBEIDSGEMEINSCHAFT FÜR NEUROPSYCHOPHARMAKOLOGIE UND PHARMAKOPSYCHIATRIE; ARI; ARIPIPRAZOLE; ASE; ASENAPINE; BRO; BROMPERIDOL; CI; CLO; CLOZAPINE; CONFIDENCE INTERVAL; DARI; DEHYDRO-ARIPIPRAZOLE; ELECTROSPRAY IONIZATION; EMA; ER; ESI; EUROPEAN MEDICINES AGENCY; EXTRACTION RECOVERY; FDA; FOOD AND DRUG ADMINISTRATION; HAL; HALOPERIDOL; HILO; HYDROXY-ILOPERIDONE; ILO; ILOPERIDONE; LC; LC-MS/MS; LEVOSULPIRIDE; LIQUID CHROMATOGRAPHY; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID-LIQUID EXTRACTION; LLE; LLOQ; LOWER LIMIT OF QUANTIFICATION; LSUL; LUR; LURASIDONE; MASS SPECTROMETRY; MATRIX EFFECTS; ME; METHYL TERT-BUTYL ETHER; MRM; MS; MTBE; MULTIPLE-REACTION MONITORING; N-DEMETHYL-CLOZAPINE; N-DEMETHYL-OLANZAPINE; NDM-CLO; NDM-OLA; NEUROLEPTICS; OLA; OLANZAPINE; PAL; PALIPERIDONE; PIP; PIPAMPERONE; QC; QUALITY CONTROL; QUE; QUETIAPINE; REDUCED HALOPERIDOL; RETENTION TIME; RHAL; RIS; RISPERIDONE; RT; SER; SERTINDOLE; SIL-IS; STABLE ISOTOPE LABELED INTERNAL STANDARD; THERAPEUTIC DRUG MONITORING; UHPLC-MS/MS; ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; ZUC; ZUCLOPENTHIXOL;

ANTIPSYCHOTIC AGENTS; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIQUID-LIQUID EXTRACTION; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84890015423     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.11.024     Document Type: Article

References (32)

1. Patteet L., Morrens M., Maudens K.E., et al. Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 2012, 34:629-651.
2. Baumann P., Hiemke C., Ulrich S., et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004, 37:243-265.
3. Hiemke C., Baumann P., Bergemann N., et al. AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 2011, 44:195-235.
4. Saar E., Beyer J., Gerostamoulos D., et al. The analysis of antipsychotic drugs in human matrices using LC-MS(/MS). Drug Test Anal 2012, 4:376-394.
5. Fisher D.S., Partridge S.J., Handley S.A., et al. LC-MS/MS of some atypical antipsychotics in human plasma, serum, oral fluid and haemolysed whole blood. Forensic Sci Int 2013, 229:145-150.
6. Juenke J.M., Brown P.I., Urry F.M., et al. Simultaneous UPLC-MS/MS assay for the detection of the traditional antipsychotics haloperidol, fluphenazine, perphenazine, and thiothixene in serum and plasma. Clin Chim Acta 2013, 423C:32-34.
7. Ansermot N., Brawand-Amey M., Kottelat A., et al. Fast quantification of ten psychotropic drugs and metabolites in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry for therapeutic drug monitoring. J Chromatogr A 2013, 1292:160-172.
8. Saar E., Gerostamoulos D., Drummer O.H., et al. Identification and quantification of 30 antipsychotics in blood using LC-MS/MS. J Mass Spectrom 2010, 45:915-925.
9. Josefsson M., Kronstrand R., Andersson J., et al. Evaluation of electrospray ionisation liquid chromatography-tandem mass spectrometry for rational determination of a number of neuroleptics and their major metabolites in human body fluids and tissues. J Chromatogr B Analyt Technol Biomed Life Sci 2003, 789:151-167.
10. Kirchherr H., Kuhn-Velten W.N. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC-tandem mass spectrometry: a multi-level, single-sample approach. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 843:100-113.
11. Kratzsch C., Peters F.T., Kraemer T., et al. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom 2003, 38:283-295.
12. Remane D., Meyer M.R., Wissenbach D.K., et al. Ultra high performance liquid chromatographic-tandem mass spectrometric multi-analyte procedure for target screening and quantification in human blood plasma: validation and application for 31 neuroleptics, 28 benzodiazepines, and Z-drugs. Anal Bioanal Chem 2011, 401:1341-1352.
13. Hasselstrom J. Quantification of antidepressants and antipsychotics in human serum by precipitation and ultra high pressure liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879:123-128.
14. Choong E., Rudaz S., Kottelat A., et al. Therapeutic drug monitoring of seven psychotropic drugs and four metabolites in human plasma by HPLC-MS. J Pharm Biomed Anal 2009, 50:1000-1008.
15. Kollroser M., Schober C. Direct-injection high performance liquid chromatography ion trap mass spectrometry for the quantitative determination of olanzapine, clozapine and N-desmethylclozapine in human plasma. Rapid Commun Mass Spectrom 2002, 16:1266-1272.
16. Roman M., Kronstrand R., Lindstedt D., et al. Quantitation of seven low-dosage antipsychotic drugs in human postmortem blood using LC-MS-MS. J Anal Toxicol 2008, 32:147-155.
17. Zhou Z., Li X., Li K., et al. Simultaneous determination of clozapine, olanzapine, risperidone and quetiapine in plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 802:257-262.
18. Sauvage F.L., Gaulier J.M., Lachatre G., et al. Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. Clin Chem 2008, 54:1519-1527.
19. Peters F.T., Drummer O.H., Musshoff F. Validation of new methods. Forensic Sci Int 2007, 165:216-224.
20. Maurer H.H. Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal Bioanal Chem 2007, 388:1315-1325.
21. U.S.Department of Health and Human Services FDA Guidance for industry: bioanalytical method validation 2001.
22. European medicines agency: Comittee for medicinal products for human use Guideline on bioanalytical method validation 2011.
23. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003, 75:3019-3030.
24. Wille S.M.R., Peters F.T., Di Fazio V., et al. Practical aspects concerning validation and quality control for forensic and clinical bioanalytical quantitative methods. Accred Qual Assur 2011, 16:279-292.
25. Fisher D.S., Partridge S.J., Handley S.A., et al. Stability of some atypical antipsychotics in human plasma, haemolysed whole blood, oral fluid, human serum and calf serum. Forensic Sci Int 2013, 229:151-156.
26. Berna M., Ackermann B., Ruterbories K., et al. Determination of olanzapine in human blood by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 767:163-168.
27. Olesen O.V., Linnet K. Determination of olanzapine in serum by high-performance liquid chromatography using ultraviolet detection considering the easy oxidability of the compound and the presence of other psychotropic drugs. J Chromatogr B 1998, 714:309-315.
28. Saar E., Gerostamoulos D., Drummer O.H., et al. Assessment of the stability of 30 antipsychotic drugs in stored blood specimens. Forensic Sci Int 2012, 215:152-158.
29. Heller S., Hiemke C., Stroba G., et al. Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. Ther Drug Monit 2004, 26:459-461.
30. Annesley T.M. Ion suppression in mass spectrometry. Clin Chem 2003, 49:1041-1044.
31. Peters F.T., Remane D. Aspects of matrix effects in applications of liquid chromatography-mass spectrometry to forensic and clinical toxicology-a review. Anal Bioanal Chem 2012, 403:2155-2172.
32. de Boer T., Meulman E., Meijering H., et al. Quantification of asenapine and three metabolites in human plasma using liquid chromatography-tandem mass spectrometry with automated solid-phase extraction: application to a phase I clinical trial with asenapine in healthy male subjects. Biomed Chromatogr 2012, 26:156-165.